Isfahan COVID cohort study: Rationale, methodology, and initial results

Nizal Sarrafzadegan1,2,*, Noushin Mohammadifard1,*, Shaghayegh Haghigho Javanmard3, Fahimeh Haghighatoost1, Fatemeh Nouri1, Mahshid Ahmadian1, Maryam Nasiran1, Maedeh Sayyah1, Jamshid Najafian1, Mohammadreza Shafiei1, Hassan Ali Khiasi2, Sahel Javanbakht14, Farzaneh Nilforoushzadeh1, Fahimeh Bagheri1, Shahla Shahidi1, Mostafa Rezaei15, Kamal Heidar16, Behrouz Keleidari15, Tahereh Changiz14

1Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran, 2Faculty of Medicine, School of Population and Public Health, University of British Columbia, Vancouver, Canada, 3Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran, 4Hypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran, 5Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran, 6Department of Noncommunicable Control, Vice Chancellery of Health Isfahan University Medical Sciences, Isfahan, Iran, 7Department of Epidemiology and Biostatistics, Health School, Isfahan University of Medical Sciences, Isfahan, Iran, 8Interventional Cardiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran, 9Executive Assistant, Vice Chancellery of Health Isfahan University Medical Sciences, Isfahan, Iran, 10Social Determinants of Health Research Center, Isfahan University of Medical Sciences, Isfahan, Iran, 11Department of Surgery, Isfahan Minimal Invasive Surgery and Obesity Research Center, Alizahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran, 12Department of Medical Education, Medical Educational Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

*Nizal Sarrafzadegan and Noushin Mohammadifard had equal contribution as first author

Background: The Isfahan COVID Cohort (ICC) study was designed to investigate the short- and long-term consequences of patients with COVID-19 in Iran. This report presents the rationale, methodology, and initial results of ICC. Materials and Methods: ICC is a 5-year multicentric prospective cohort study that is ongoing on two groups including 5000 patients hospitalized with moderate or severe and 800 nonhospitalized patients with mild or asymptomatic COVID-19 in Isfahan. The ICC endpoints are morbidity, mortality, incident cases, or worsening of underlying noncommunicable diseases (NCDs) and their risk factors. In the current analysis, we examined the persistent symptoms and incident NCDs or risk factors in 819 previously hospitalized patients who completed 1-year follow-up. Results: The two most common symptoms were joint pain/myalgia (19.7%) and dry cough/dyspnea (18.7%). Around 60% of patients had at least one symptom which was more common among women than men and in middle aged than younger or older patients. Female (odds ratio [OR] =1.88, 95% confidence interval [CI]: 1.39–2.55) and highly-educated patients (OR = 2.18, 95% CI: 1.56–3.04) had higher risk of having any symptom in 1-year follow-up. New cases of hypertension followed by diabetes then coronary heart disease (CHD) were the most common incident NCDs. Conclusion: During 1-year follow-up after hospital discharge, about 60% of patients experienced persistent symptoms. Incident hypertension, diabetes, and CHD were the most common events seen. Close monitoring and extensive health services with integrative approaches are needed to improve the health status of these patients.

Key words: COVID-19, morbidity, mortality, outcome, prospective cohort study, symptom

How to cite this article: Sarrafzadegan N, Mohammadifard N, Javanmard SH, Haghighatoost F, Nouri F, Ahmadian M, et al. Isfahan COVID cohort study: Rationale, methodology, and initial results. J Res Med Sci 2022;27:65.
INTRODUCTION

COVID-19 pandemic is a new unexpected health system challenge to our world,[1] which is encountered with another epidemic of noncommunicable diseases (NCD).[2] Evidence have shown that NCDs can predict poor prognosis in patients with COVID-19.[3] Recent meta-analysis indicated that hypertension, chronic respiratory disease (CRD), and cardiovascular disease (CVD) were associated with severe COVID-19.[3] Another meta-analysis including 3403 COVID-19 patients revealed that the most prevalent comorbidities in patients with COVID-19 were hypertension 16.4%, CVD 12.1%, and diabetes mellitus (DM) 7.9%.[4]

Previous reports from SARS and MERS infection which shares considerable similarity with COVID-19 have shown that among patients who had recovered from SARS, 68% continued to have abnormalities of lipid metabolism at 12-year follow-up; cardiovascular (CV) abnormalities were present in 40% and altered glucose metabolism in 60%.[5,6] Similar findings have also been reported in patients recovering from other respiratory tract infections.[5,6]

Long-term health consequences of COVID-19 remain largely unclear after recovery of this illness. There are not sufficient data available about the immunity after recovery from COVID-19 that might confer immunity against reinfection.[7] Excess death in a crisis-related period compared to expected death rate in nonpandemic period of time can be attributed to COVID-19, but it has been reported as mortality from ischemic heart disease, stroke, and chronic obstructive pulmonary disease.[8,9] Moreover, several studies have been reported the many people complaint from the long COVID pulmonary disease.

Evidence have shown that NCDs can predict poor prognosis in patients with COVID-19. The interim guidance of the World Health Organization (WHO) has been used to diagnose COVID-19[13] and for hospitalization. Therefore, patients with positive result of reverse transcription-polymerase chain reaction (RT-PCR) and have been hospitalized if they have been diagnosed as having severe or moderate symptoms such as respiratory rate > 30 breaths per minute, oxygen saturation <94% on room air at sea level, ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO₂/FIO₂) <300 mmHg, or lung infiltrates >50%. Those who died after discharge and before recruitment in our study will undergo verbal autopsy Figure 1.

In addition, we are recruiting those who have been referred to health centers because of a new experience of mild symptoms of COVID-19 or have been exposed to someone with COVID-19 and are asymptomatic but have positive results of RT-PCR test for coronavirus.[13] We did not consider limitations such as age, sex, pregnancy, or lactation and our recruitment started since March 10, 2020. Our exclusion criteria were hospitalized patients before March 10, 2020, and patients who did not have a RT-PCR test for COVID-19 or negative test results of RT-PCR.

To date, we have recruited 3040 hospitalized patients in our cohort study but followed 819 of them for 1 year by...
phone calls. We will continue recruiting until reaching our complete samples in both groups. For the baseline phase of this cohort study, we obtained patients’ address and phone numbers from the Integrated Health System (SIB) dataset in health centers and contacted them to attend health centers with all their previous medical documents related to the period of time before and after their hospitalization for COVID-19. Upon arrival to the health centers, we explained the whole study and follow-up and obtained consent forms from all patients. Then, we completed three types of questionnaires including demographic and socioeconomic, prevention, and hygiene; lifestyle behaviors and practices; and clinical course during hospitalization. In addition, we completed medical history and did complete physical examination for each patient during their presence in health centers. This study was approved by the Ethics Committee of Isfahan University of Medical Sciences (IUMS) (No: IR.MUI.MED.REC.1399.223).

**Data collection**

**Demographic, socioeconomic, hygiene and prevention practice questionnaires**

First, data regarding demographic and socioeconomic status were collected. Other questions in our first questionnaire were on participants’ knowledge and practice before and after hospitalization for COVID-19 regarding quarantine, social distance, wearing masks, disinfecting surfaces, cloths, and methods of disinfection. We also asked patients on their considering hygiene recommendations in work place and shopping, as well as their information on the source of COVID-19 transmission and how they were infected, etc. Trained staff of health center have completed our online questionnaire.

**Lifestyle behavior questionnaire**

Using a valid and reliable questionnaire as ICC second questionnaire, we examined lifestyle characteristics including...
For blood pressure measurements, participants have been asked to avoid any severe physical activity, eating and drinking any type of liquids (except for water), smoking, and consuming any medicine which affects blood pressure at least 1 h before the measurement. Using an OMRON barometer, the blood pressure was measured by trained nurses while participants were sitting and rested at least for 5 min before measurement. Measurements were done twice from each arm, and the mean value of all measurements was recorded as the final value for blood pressure.  

**Questionnaire on clinical course during hospitalization**

Another questionnaire which is the 4th one in ICC study was developed to study the hospitalization clinical course and was completed using the patients’ medical records in hospitals. There have been questions that cover all clinical findings, patients’ outcomes and signs of severity, need for mechanical ventilation and transfer to intensive care unit, medicines used, lab tests, comorbidities such as underlying NCDs, length of hospitalization in different units, and reasons for transferring patients to different units. These data were collected by trained nurses in each COVID-19 referral hospital.

**Blood sample collection**

A blood sample was obtained from each participant to test immunoglobulin (Ig) G and IgM. All blood samples were transferred to the Isfahan Cardiovascular Research Institute laboratory, which is a WHO Collaborating center in the Eastern Mediterranean Region (EMR). In addition, we collected whole blood samples and stored it in −80°C freezers for future studies including genetic or epigenetic ones.

**Follow-ups**

At the end of 6 months of basic visits to health centers, patients were contacted, then on annual basis until 5 years. Our staff had called all participants asking for their symptoms, new events or worsening of the underlying NCDs or risk factors that they had during their hospitalization, new diagnostics or treatment approaches, and reinfection. If participants report any of the above, they were invited to our COVID-19 clinic for further investigations. Patients are visited by an internal medicine specialist in this clinic, if the internist needs further investigation by other subspecialty, he could refer them to different subspecialty physicians to perform complementary diagnostic tests such as electrocardiography, echocardiography, fitness test, spirometry, renal or liver function tests or ultrasound among others. Furthermore, all patients were provided by the COVID-19 clinic phone numbers to contact our staff if they face any medical problem, hospitalization, new diagnostic tests, or treatments in the period of time between our 5 annual follow-ups [Figure 1].

**Medical history and physical examination questionnaire**

In our third questionnaire, all medical history related to the time before or after hospitalization for COVID-19 on the existence of NCDs including CVD such as coronary heart disease (CHD), hypertension, CRD, DM, cancers, and chronic kidney disease (CKD) as well as previous history of all medicines used for these NCDs and their risk factors have been obtained by interviewing patients in health centers. If patients indicate any other NCD or medicines used that have not been included in our questions, it was added to the questionnaire. In addition, persistent COVID symptoms or any new symptoms were asked during follow-ups. The medical history was completed by trained health centers’ general practitioners (GPs).

GPs in health centers performed general physical examinations and completed our checklists. If patients develop new sign and symptoms after discharge from hospitals, they were referred by GPs to our COVID-19 clinic and internal medicine specialist visited them. GPs in health centers have informed all patients to attend this clinic if they face any problem after their baseline examination and during the 5 years of follow-up.

**Anthropometric and blood pressure measurements**

Trained staff in health centers measured anthropometric variables that consist of height, weight, waist, hip, and neck circumferences (NCs), while GPs measured the patients’ blood pressure. Body weight was measured using a standard digital scale and recorded to the nearest 0.5 kg. Height was measured using an inelastic tape measure and recorded to the nearest 0.5 cm. Body mass index was calculated by dividing weight (Kg) to height (m) square. Waist circumference was measured at the at the approximate midpoint between the lower margin of the last palpable rib and the top of the iliac crest, and hip circumference measurement was taken around the widest portion of the buttocks using an inelastic tape to the nearest 0.1 cm, respectively. The NC was measured below the cricoid cartilage, at the level of the midcervical spine.

smoking, dietary habits, alcohol use, psychological factors, physical activity, and drug abuse. We assessed dietary habits using a validated food frequency questionnaire, mental health status using a validated Persian version of hospital anxiety and depression scale and perceived stress scale, tobacco smoking habits using global adult tobacco survey questionnaire which was designed by the Centers for Disease Control and Prevention and WHO, drug abuse using a validated questionnaire in Iran, and physical activity using international physical activity questionnaires. All questionnaires were completed online by interviewers who were trained on how to complete online questionnaires.
At the end of the 5th year of follow-up, all baseline measurements will be repeated using the same tools such as questionnaires and the same process as of the baseline study. If any new event happens during the 5-year follow-up, a panel including 3 specialists in the field of the event and related fields would examine and study the patient documents and decide on final diagnosis.

**Outcomes**

**Primary outcomes**
They include all-cause and cause-specific mortality, incident cases or worsening of underlying NCDs and their risk factors, as well as persistent symptoms or any new symptom following COVID-19.

**Secondary outcomes**
Any hospitalization and new diagnostic or treatment prescribed to the patients will be investigated. Furthermore, reinfection of COVID-19 or the occurrence of other infectious diseases, will be considered [Figure 1].

**Statistical analysis**
We utilized SPSS Statistics for Windows, version 25 (SPSS Inc., Chicago, Ill., USA). We presented continuous variables as means and standard deviations (SDs) and categorical variables including as frequency and percentages. The logistic regression was used to estimate the odds ratio (OR) (95% confidence interval [CI]) (OR [95% CI]) of long COVID symptoms by adjusting for age (year), sex (male/female), education (middle school or lower/high school or university), and smoking (ever smoker/nonsmoker). \(P < 0.05\) was considered statistically significant.

**RESULTS**

General characteristics of the patients based on sex are shown in Table 1. The mean age was 56.7 ± 14.3 years. The majority of subjects (almost 80%) aged over 45 years and this proportion was almost identical between men and women. Women had lower educational level compared to men. The prevalence of smoking was 3.9%, 6.1%, and

| Table 1: Basic characteristics according to sex |
|-----------------------------------------------|
|                                      Overall \((n=819), n (%)\) | Men \((n=489), n (%)\) | Women \((n=330), n (%)\) |
|---------------------------------|----------------|----------------|
| **Age (years), mean±SD**       | 56.7±14.3     | 57.5±14.1     | 55.6±14.6     |
| **Age group (years)**          |                |                |
| <45                             | 168 (20.5)    | 91 (18.6)     | 77 (23.3)     |
| 45–60                           | 317 (38.7)    | 189 (38.7)    | 128 (38.8)    |
| >60                             | 334 (40.8)    | 209 (42.7)    | 125 (37.9)    |
| **Education**                   |                |                |
| Middle school or lower          | 464 (56.7)    | 249 (50.9)    | 215 (65.2)    |
| High school or university       | 355 (43.3)    | 240 (49.1)    | 115 (34.8)    |
| **Smoking status**              |                |                |
| Never smoker                    | 728 (88.9)    | 403 (82.4)    | 325 (98.5)    |
| Current smoker                  | 32 (3.9)      | 30 (6.1)      | 2 (0.6)       |
| Former smoker                   | 59 (7.2)      | 56 (11.5)     | 3 (0.9)       |
| Alcohol use                     | 27 (3.3)      | 24 (4.9)      | 3 (0.9)       |
| **Underlying NCD**              |                |                |
| DM                              | 226 (27.6)    | 136 (27.8)    | 90 (27.3)     |
| Hypertension                    | 316 (38.6)    | 172 (35.2)    | 144 (43.6)    |
| CHD                             | 152 (18.6)    | 98 (20.0)     | 54 (16.4)     |
| CRD                             | 63 (7.7)      | 40 (8.2)      | 23 (7.0)      |
| Cancer                          | 24 (2.9)      | 13 (2.7)      | 11 (3.3)      |
| CKD                             | 36 (4.4)      | 21 (4.5)      | 15 (4.2)      |
| Any NCD                         | 359 (56.2)    | 216 (55.8)    | 143 (56.7)    |
| **Hospitalization**             |                |                |
| Length of hospitalization (days)|                |                |
| Mean±SD                         | 6.7±5.2       | 7.0±5.1       | 6.4±5.3       |
| Median (minimum–maximum)        | 5 (2–21)      | 6 (2–18)      | 5 (2–21)      |
| ICU admission                   | 81 (9.9)      | 49 (10.0)     | 32 (9.7)      |
| Length of ICU stay (days)       |                |                |
| Mean±SD                         | 5.5±3.7       | 5.8±3.9       | 5.1±3.6       |
| Median (minimum–maximum)        | 5 (2–12)      | 5 (2–12)      | 5 (2–11)      |
| Mechanical ventilation          | 13 (1.6)      | 8 (1.6)       | 5 (1.5)       |
| \(\text{O}_2\) saturation<93%   | 515 (62.9)    | 314 (64.2)    | 201 (60.9)    |

SD=Standard deviation; ICU=Intensive care unit; DM=Diabetes mellitus; CHD=Coronary heart disease; CRD=Chronic respiratory disease; CKD=Chronic kidney disease; NCD=Noncommunicable disease
0.6% in total, men, and women, respectively. Alcohol was consumed by 3.3% of participants, particularly in male patients (4.9%). The distribution of underlying NCDs during hospitalization was similar between men and women. The first prevalent disease was hypertension (35.2% in men and 43.6% in women), followed by DM (27.8% in men and 27.3% in women), CHD (20.0% in men and 16.4% in women), and CRD (8.2% in men and 7.0% in women). Cancer and CKD were present in a smaller fraction of our study population.

On average, the duration of hospitalization was 6.7 ± 5.2 days, which did not differ considerably between men and women. Although the need for mechanical ventilation was similar between men and women, suffering from low O₂ saturation was higher among men.

Table 2 reveals the prevalence of various postdischarge symptoms after 1-year follow-up of hospitalized patients with COVID-19. The first and second most common symptoms were joint pain or myalgia and dry cough or dyspnea, with a prevalence of 19.7% and 18.7%, respectively. In addition, 14.7% reported hair loss and either fatigue or muscle weakness (11.7%). The prevalence of other symptoms was around 6% or less. The order of prevalent symptoms in men was dry cough or dyspnea followed by joint pain or myalgia. In women, however, the first symptom was hair loss, which affected almost one-fourth of the total sample followed by joint pain or myalgia then dry cough or dyspnea and the last was fatigue or muscle weakness. Around 40% of patients had no symptoms in 1-year of follow-up, of which a larger proportion of men experienced no symptoms compared to women (45.8% vs. 33.6%).

Further analysis for the prevalence of various symptoms according to the age groups revealed that middle-aged patients experienced any of the reported symptoms more than younger (≤45 year) and older (>60 year) patients. In other words, two-thirds of middle-aged subjects had at least one symptom in 1-year follow-up, while this figure was 60% and 50% in young and older patients, respectively [Table 2]. Having two symptoms or more was similar in all three age groups. The first two prevalent symptoms in middle-aged were dry cough or dyspnea and joint pain or myalgia which affected almost one in four and they were 14.1%,
and 15.9% in older patients, respectively. The figure for the young age group were 16.1% and 17.3%, respectively. In contrast, the first common symptom in the young was hair loss, affecting around one-fourth, and 16% and 9% of middle-aged and older patients, respectively. Older patients than that of for two other age groups was more susceptible renal disorders (2.1% in the old, 0.9% in the middle-aged, and 0.6% in the young). In men, the frequency of one and at least two symptoms was approximately equal (27%). However, in women, the proportion of patients with two symptoms and over was higher and about 40%.

The occurrence of various outcomes during 1 year of follow-up in hospitalized patients with COVID-19 stratified by sex is shown in Table 3. New incident cases of CHD, DM, and hypertension were seen in 2.4%, 3.2%, and 4.4% of patients in 1-year follow-up, respectively. A smaller proportion of our studied population developed CRD (1.1%) or stroke (0.1%). In addition, while 1.2% of women were hospitalized due to any reason, only 0.2% of men and 0.5% in total were hospitalized due to any reason.

Figure 2 presents the OR (95% CIs) of the association of COVID-19 with the presence of any of the examined symptoms according to some of general characteristics. Our results revealed that females (OR = 1.88, 95% CI: 1.39, 2.55) and highly-educated patients (OR = 2.18, 95% CI: 1.56, 3.04) had higher risk of having any of the examined symptoms compared with men and lower educated patients. However, age (OR = 1.00, 95% CI: 0.98, 1.01) and having any of the NCDs as underlying disease during hospitalization (OR = 1.16, 95% CI: 0.83, 1.61) could not predict the risk of the presence of any of the reported symptoms in 1-year follow-up.

DISCUSSION

To our knowledge, the ICC study is the largest ongoing prospective cohort study with long follow-up of patients and wide range of COVID-19 severity including asymptomatic and mild at community level as well as moderate and severe hospitalized cases to investigate the short- and long-term morbidity, mortality symptoms, incident cases, or worsening of NCDs and its risk factors in the EMR. In this article, we present the methodology and initial results of symptoms and some incident NCDs of only hospitalized patients with COVID-19 during the 1st year of follow-up. We found that about 60% of participants had at least one COVID-19 persistent or new symptom in the 1st year of follow-up, which indicates a probable multisystem involvement. These symptoms are more frequent in women than men and highest in 45–60 years’ age group. Myalgia or join pain, dry cough or dyspnea, hair loss and fatigue, or muscle weakness are the four most common symptoms in 1-year follow-up, which mostly terrified our patients. As we have completed additional questions on prehospitalization, we are able to present pre-COVID data for comparison in future reports.

ICC study advantages compared to other long COVID cohort studies in the UK, USA, Netherland, France, Russia, and China are its large sample size of 5800 from the community and hospitals with annually follow-up until 5 years. In addition, we completed wide range of questionnaires to collect data on demographic, socioeconomic, prevention, and hygiene practices and lifestyle habits such as dietary, smoking, addiction, physical inactivity, and psychological

| Outcomes                                | Overall (n=819), n (%) | Men (n=489), n (%) | Women (n=330), n (%) |
|-----------------------------------------|------------------------|--------------------|----------------------|
| CHD                                     | 20 (2.4)               | 10 (2.0)           | 10 (3.0)             |
| Stroke                                  | 1 (0.1)                | 1 (0.2)            | 0 (0.0)              |
| CRD                                     | 9 (1.1)                | 5 (1.0)            | 4 (1.2)              |
| NCD risk factors                        |                        |                    |                      |
| New case of DM                          | 15 (3.2)               | 8 (3.0)            | 7 (3.4)              |
| Uncontrolled DM                         | 11 (7.2)               | 6 (7.3)            | 5 (7.1)              |
| New case of hypertension                | 21 (4.4)               | 12 (4.5)           | 9 (4.4)              |
| Uncontrolled hypertension               | 10 (5.3)               | 5 (5.4)            | 5 (5.3)              |
| Any hospitalization                     | 5 (0.5)                | 1 (0.2)            | 4 (1.2)              |

DM=Diabetes mellitus; CHD=Coronary heart disease; CRD=Chronic respiratory disease; NCD=Noncommunicable disease
In contrast to our findings, various long COVID cohort studies in the US, European countries, and China reported the incidence of at least one symptom in 30%–88% with an average of 50% of patients who were hospitalized with COVID-19 during a postdischarge follow-up of 1–6 months. About 50% of the patients reported at least one GP visit during their postinfection period in Germany. However, most of mild COVID-19 cases have returned to their normal health status after 1 or 2 months. In contrast to our findings, an early report from Wuhan, China, showed that persistent postdischarge symptoms of COVID-19 have been recovered in 86% before the end of the 1st month. Our results showed that to be free of any symptom or to return to normal health and life might take more than 1 year after discharge in moderate and severe COVID-19 cases.

In the Consultation Multi-Expertise de Bicêtre Après COVID-19 study in France, fatigue cognitive symptoms, and new-onset dyspnea were reported after 4 months in 31%, 21%, and 16% of patients, respectively. Another study showed that in 23% of noncritical COVID-19 patients had complaints from anosmia/ageusia, 30% from dyspnea, 40% from asthena and 15% from chest pain in 40% of patients during 2-months of follow-up. Consistent to our study, the follow-up evaluation after 1 month of discharge was declarative over a phone call without physical examination in various long COVID studies. Similarly, former studies of SARS, H1N1, and Ebola revealed that fatigue, myalgia, and breathlessness were persistent for long time after discharge in more than half of patients even after 1 year. A Canadian study reported that 40% of SARS survivors still had a chronic fatigue problem for a mean period of 41.3 months of follow-up. Various studies had inconsistent results about the determinants of persistent symptoms such as age and sex. Keeping in line with our study, several studies found that persistent symptoms of COVID-19 were associated with female gender, but Petersen et al. could not find any association with sex. Similar to our study, the persistent symptoms were seen more in 40–60 years’ age group. While our findings did not show age as a predictor of persistent symptoms, in contrast, in the UK study, age was the main risk factor for persistent symptoms. Preexisting chronic disease had with long COVID symptom in Petersen et al.’ study, which is in agreement to our study. Few studies evaluated the association of education with persistent symptom occurrence, though we found the positive strong relationship between education and any symptom incidence. Owing to our self-reported approach first in the 1-year follow-up, it might be due to their more attention and worriedness about their health status, hence their over reporting compared to lower educated patients.

Various reported long-term postdischarge symptoms among COVID-19 patients such as fatigue, dyspnea, bone and joint pain, arthralgias, physical decline, myalgia, chest pain, hair loss, cough, anosmia, ageusia, difficulty concentrating, decreased appetite, headaches, sleep disorders, memory loss, confusion, psychological distress, fever, and dizziness. In contrast to our findings, the most prevalent symptom in several studies was fatigue or muscle weakness by 31%–72%. However, in some reports, it was fever up to 87% followed by cough, fatigue, and dyspnea, particularly in patients with severe COVID-19. This inconsistency might be due to our longer follow-up, which is about 1 year compared with up to 6 months in former reports. In addition, most of these symptoms are multidimensional health problems that can overlap with each other.

The potential mechanisms are unknown; however, like other viral infections, the long COVID symptoms might be linked with the sequela of central nerve system injury by SARS-CoV-2. Recent evidence stated that COVID-19-prolonged outcomes might be attributed to the mast cell activation syndrome 32 and the Th-2 biased immunological response in allergic diseases. Moreover, inflammatory response related to symptomatic COVID-19 and posttraumatic stress disorder after COVID-19 might cause long-term symptoms. Neurological COVID-19 sequelae can prove involvement of central and peripheral nervous system, which leads to expressing angiotensin-converting enzyme 2 (ACE2) receptor in muscle and neural tissue, thus causing the speculation of potential neurotropism. Hence, COVID-19 can promote a large care burden after the pandemic is ended. It requires more attention and efforts of health system. However, the frequency of patients with CVD in this cohort is fairly low, since self-reported by patients might lead to underestimation.

To date, most studies have provided data on long COVID symptoms, rather than multiorgan dysfunction, and a few studies have reported the incidence of NCDs such as CHD, stroke, and CRD as well as new cases of hypertension and DM. During 1-year follow-up, a remarkable proportion of new cases and uncontrolled DM as well as hypertension have been occurred in the current study. Similarly, a prospective cohort study in UK on more than 47,000 discharged patients
with the mean follow-up of about 5 months had new onset of DM and major adverse CV events by 2.5% and 7%, respectively.[51] Some researchers proposed that diabetes may indirectly result from severe COVID-19 illness. The coronavirus could promote development of Type 2 diabetes or more uncontrolled state in high-risk patients like those with prediabetes, obesity, and hypertension. In agreement to our study, a cohort study in Italy revealed that uncontrolled hypertension was extremely prevalent, which may due to the association of that SARS-CoV-2 infection and CV injury.[52] SARS-CoV-2 pass cell membrane by leveraging the ACE2 receptor, a leading regulator of the renin-angiotensin system. The most spike glycoprotein of the virus binds to ACE2; however, proximal serine proteases cleave the viral spike protein and ACE2, to stimulate virus entrance. Cell death due to infection activates inflammatory cytokine production, inflammatory immune cell recruitment circulation of immune cells, stimulation of lymphocyte apoptosis, and inflammatory cytokine secretion, known as “cytokine storm.” It can develop multiorgan failure, raise blood pressure, disrupt endocrine signaling, and consequently induce hyperglycemia.[53] Acute kidney injury COVID-19 infection can prompt renal failure and hence elevated blood pressure in those with prior normotensive.[54] Therefore, using effective strategies such as lifestyle modification and proper medication can be applied to manage CVD and its risk factors and subsequently reduce the burden of COVID-19 pandemic.

Strength and limitation
This report which is a part of the ICC study has some strengths that include the multicentric design with a large sample size of postdischarged patients with COVID-19. Another strength is the long follow-up of these patients for 1 year. However, the absence of pre-COVID-19 assessments in this article is one of our limitations and similar to other studies, but we will report it in our future articles. Another limitation is we have not reported the psychological and psychosomatic variables in this paper.

CONCLUSIONS
So far, the ICC study has been the largest ongoing prospective cohort study with the longest follow-up of patients with wide range of COVID-19 severity from asymptomatic to severe cases to investigate the persistent symptoms, short- and long-term morbidity, incident and worsening NCDs and their risk factors, and mortality of COVID-19 in Iran and the EMR.

Following 1 year of our patients discharge, about 60% experienced persistent symptoms with the most common being myalgia or joint pain, dry cough or dyspnea, hair loss, fatigue, or muscle weakness. It was more frequent in women than men and most common in 45–60 years’ age group. New cases of hypertension then diabetes followed by CHD were the most incident NCDs seen in our 1-year follow-up, with higher prevalence in women compared to men. Therefore, our findings showed that extensive health services and integrative approaches are needed to improve health status of patients with COVID-19 after their discharge. Along with effort to control the spread of COVID-19 infection, it is critical to plan for human and financial resources to diminish the burden from long COVID. Although the management of acute phase of COVID-19 is still challenging, its long-term symptoms and events may create major problems for survivors, their families, and the society.

Acknowledgment
ICC study has been supported by grant number 199093 from the IUMS, grant number RPPH 20-76 from the WHO/EMR, grant number 996353 from the National Institute of Health Researches of Iran, and grant number 99008516 from the Iran National Science Foundation.

We express our special thanks and deep gratitude to all physicians, nurses, and other staff who were frontline health care providers in all COVID-19 referral hospitals. We would like to thank all the patients and their families who provided consents for participation in our study. The efforts of all staff of health centers in Isfahan province are highly appreciated.

Financial support and sponsorship
ICC study has been supported by grant number 199093 from the IUMS, grant number RPPH 20-76 from the WHO/EMR, grant number 996353 from the National Institute for Medical Research Development of Iran, and grant number 99008516 from the Iran National Science Foundation.

Conflicts of interest
There are no conflicts of interest.

REFERENCES
1. Barouki R, Kogevinas M, Audouze K, Belesova K, Bergman A, Birnbaum L, et al. The COVID-19 pandemic and global environmental change: Emerging research needs. Environ Int 2021;146:106272.
2. Horton R. Offline: Time to radically rethink non-communicable diseases. Lancet 2019;393:1922.
3. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: A systematic review and meta-analysis. Int J Infect Dis 2020;94:91-5.
4. Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of underlying diseases in hospitalized patients with COVID-19: A systematic review and meta-analysis. Arch Acad Emerg Med 2020;8:e35.
5. Corrales-Medina VF, Alvarez KN, Weissfeld LA, Angus DC, Chirinos JA, Chang CC, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease.
Sarrafzadegan, et al.: Methodology of Isfahan COVID Cohort Study

JAMA 2015;313:264-74.

6. Wu Q, Zhou L, Sun X, Yan Z, Hu C, Wu J, et al. Altered lipid metabolism in recovered SARS patients twelve years after infection. Sci Rep 2017;7:9110.

7. Kirkclady RD, King BA, Brooks JT. COVID-19 and postinfection immunity: Limited evidence, many remaining questions. JAMA 2020;323:2245-6.

8. GBD 2019 Demographics Collaborators. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: A comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396:1160-203.

9. Jannamsh SH, Mohamadifard N, Nasirian M, Vaseghi G, Heidari K, Keliabadi B, et al. COVID-19 and interaction with noncommunicable disease: Results based on I-CORE registry. East Mediterr Health J 2021;27:1036-44.

10. Arnold DT, Hamilton FW, Milne A, Morley AJ, Viner J, Attwood M, et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: Results from a prospective UK cohort. Thorax 2021;76:399-401.

11. Halpin SJ, McVor C, Whyatt G, Adams A, Harvey O, McLean L, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J Med Virol 2021;93:1013-22.

12. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet 2021;397:220-32.

13. World Health O. Clinical Management of Severe Acute Respiratory Infection when Novel Coronavirus (2019-nCoV) Infection Is Suspected: Interim Guidance, 28 January 2020. Geneva: World Health Organization; 2020.

14. Mohammadifard N, Sajjadi F, Maghrour M, Alikhasi H, Nilforouzshadzeh F, Sarrafzadegan N. Validation of a simplified food frequency questionnaire for the assessment of dietary habits in Iranian adults: Isfahan Healthy Heart Program, Iran. ARYA Atheroscler 2015;11:139-46.

15. Montazeri A, Vahdaninia M, Ebrahimyi M, Jarvandi S. The Hospital Anxiety and Depression Scale (HADS): Translation and validation study of the Iranian version. Health Qual Life Outcomes 2003;1:1-4.

16. Nouri M, Ghaffarifar S, Sadeghi-Bazargani H. Development of the Persian patient satisfaction questionnaire. Int J Health Care Qual Assur 2018;31:988-99.

17. Global Adult Tobacco Survey Collaborative Group. Global Adult Tobacco Survey (GATS): Core Questionnaire with Optional Questions. Atlanta, GA: Centers for Disease Control and Prevention, 2020.

18. Geramian N, Gharaat L, Taheri SA, Mohepour F, Nazivzadeh M, Farrajzadegan Z, et al. Development of a Questionnaire to Assess Drug Abuse among High School Students of Isfahan Province, Iran: An Action Research. Int J Prev Med 2014;5:5146-53.

19. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003;35:1381-95.

20. WHO STEPS Surveillance Manual: The WHO STEPSwise approach to chronic disease risk factor surveillance. Geneva, World Health Organization; 2005.

21. Nishida C, Ko GT, Kumanyika S. Body fat distribution and noncommunicable diseases in populations: Overview of the 2008 WHO Expert Consultation on Waist Circumference and Waist-Hip Ratio. Eur J Clin Nutr 2010;64:2-5.

22. Saka M, Türker P, Ercan A, Kiziltan G, Baş M. Is neck circumference measurement an indicator for abdominal obesity? A pilot study on Turkish Adults. Afr Health Sci 2014;14:570-5.

23. Bonita R, Winkelmann R, Douglas KA, de Courten M. The WHO Stepwise Approach to Surveillance (STEPS) of Non-Communicable Disease Risk Factors. Global Behavioral Risk Factor In: McQueen DV, Fusura P. (eds) Global Behavioral Risk Factor Surveillance. Springer, Boston; 2003, p. 9-22.

24. Writing Committee for the COMEBAE Study Group, Morin L, Savale L, Pham T, Colle R, Figueiredo S, et al. Four-month clinical status of a cohort of patients after hospitalization for COVID-19. JAMA 2021;325:1525-34.

25. Carvalho-Schneider C, Laurent E, Lemaignen A, Beaufils E, Bourbou-Tournois C, Laribi S, et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect 2021;27:258-63.

26. Marshall M. How COVID-19 can damage the brain. Nature. 2020;585:342-3.

27. Carfi A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA 2020;324:603-5.

28. Arnold DT, Hamilton FW, Milne A, Morley AJ, Viner J, Attwood M, et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax 2021;76:399-401.

29. Gubbajtsson DF, Helgason A, Jonsson H, Magnusson OT, Melsted P, Norddahl GL, et al. Spread of SARS-CoV-2 in the Icelandic population. N Engl J Med 2020;382:2302-15.

30. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill 2020;25:2000180.

31. Zhu J, Ji P, Pang J, Zhou Z, Li H, He C, et al. Clinical characteristics of 3062 COVID-19 patients: A meta-analysis. J Med Virol 2020;92:1902-14.

32. Lavezzo E, Franchin E, Ciavarella C, Cuomo-Dannenburg G, Barzon L, Del Vecchio C, et al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'. Nature 2020;584:425-9.

33. Petersen MS, Kristiansen MF, Hanusson KD, Danielsen ME, Á Steig B, Gains B, et al. Long COVID in the Faroe Islands: A longitudinal study among nonhospitalized patients. Clin Infect Dis. 2021;73:e4058-e63.

34. Moreno-Pérez O, Merino E, Leon-Ramírez JM, Andres M, Ramos JM, Arenas-Jiménez J, et al. Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study. J Infect 2021;82:578-83.

35. Wang X, Xu H, Jiang H, Wang L, Lu C, Wei X, et al. Clinical features and outcomes of discharged coronavirus disease 2019 patients: A prospective cohort study. QJM 2020;113:657-65.

36. Wu X, Dong D, Ma D. Thin-section computed tomography manifestations during convalescence and long-term follow-up of patients with severe acute respiratory syndrome (SARS). Med Sci Monit 2016;22:2793-9.

37. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20.

38. Islam MF, Cotler J, Jason LA. Post-viral fatigue and COVID-19: Lessons from past epidemics. Biomed Health Behav 2020;8:61-9.

39. Lam MH, Wing YK, Yu MW, Leung CM, Ma RC, Kong AP, et al. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: Long-term follow-up. Arch Intern Med 2009;169:2142-7.

40. Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: A single-centre longitudinal study. Clin Microbiol Infect 2021;27:89-95.

41. Sigfrid L, Drake TM, Pauley E, Jesudason EC, Olliaro P, Lim WS, et al. Long Covid in Adults Discharged From UK Hospitals After
Covid-19: A Prospective, Multicentre Cohort Study Using the ISARIC WHO Clinical Characterisation Protocol; Lancet Reg Health Eur 2021;8:100186.

42. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med 2021;27:626-31.

43. Garrigues E, Janvier P, Kherabi Y, Le Bot A, Hamon A, Gouze H, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect 2020;81:e4-6.

44. Rass V, Beer R, Schiefecker AJ, Kofler M, Lindner A, Mahlknecht P, et al. Neurological outcome and quality of life 3 months after COVID-19: A prospective observational cohort study. Eur J Neurol 2021;28:3348-59.

45. Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS, et al. ‘Long-COVID’: A cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax 2021;76:396-8.

46. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med 2020;8:475-81.

47. White PD, Dash AR, Thomas JM. Poor concentration and the ability to process information after glandular fever. J Psychosom Res 1998;44:269-78.

48. Mahase E. Covid-19: What do we know about “long covid”? BMJ 2020;370:m2815.

49. Xiao S, Luo D, Xiao Y. Survivors of COVID-19 are at high risk of posttraumatic stress disorder. Glob Health Res Policy 2020;5:29.

50. Miyamae Y, Hayashi T, Yonezawa H, Fujihara J, Matsumoto Y, Ito T, et al. Duration of viral shedding in asymptomatic or mild cases of novel coronavirus disease 2019 (COVID-19) from a cruise ship: A single-hospital experience in Tokyo, Japan. Int J Infect Dis 2020;97:293-5.

51. Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond I, et al. Post-covid syndrome in individuals admitted to hospital with covid-19: Retrospective cohort study. BMJ 2021;372:n693.

52. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020;17:259-60.

53. Feldman EL, Savelieff MG, Hayek SS, Pennathur S, Kretzler M, Pop-Busui R. COVID-19 and Diabetes: A Collision and Collusion of Two Diseases. Diabetes 2020;69:2549-65.

54. Schiffrin EL, Flack JM, Ito S, Mintner P, Webb RC. Hypertension and COVID-19. Am J Hypertens 2020;33:373-4.